» Articles » PMID: 32758278

Who Knew? The Misleading Specificity of "double-blind" and What to Do About It

Overview
Journal Trials
Publisher Biomed Central
Date 2020 Aug 8
PMID 32758278
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In randomized trials, the term "double-blind" (and its derivatives, single- and triple-blind, fully blind, and partially blind or masked) has no standard or widely accepted definition. Agreement about which groups are blinded is poor, and authors using these terms often do not identify which groups were blinded, despite specific reporting guidelines to the contrary. Nevertheless, many readers assume-incorrectly-that they know which groups are blinded. Thus, the term is ambiguous at best, misleading at worst, and, in either case, interferes with the accurate reporting, interpretation, and evaluation of randomized trials. The problems with the terms have been thoroughly documented in the literature, and many authors have recommended that they be abandoned.

Proposal: We and our co-signers suggest eliminating the use of adjectives that modify "blinding" in randomized trials; a trial would be described as either blinded or unblinded. We also propose that authors report in a standard table which groups or individuals were blinded, what they were blinded to, how blinding was implemented, and whether blinding was maintained. Individuals with dual responsibilities, such as caregiving and data collecting, would also be identified. If blinding was compromised, authors should describe the potential implications of the loss of blinding on interpreting the results.

Conclusion: "Double blind" and its derivatives are terms with little to recommend their continued use. Eliminating the use of adjectives that impart a false specificity to the term would reduce misinterpretations, and recommending that authors report who was blinded to what and how in a standard table would require them to be specific about which groups and individuals were blinded.

Citing Articles

Comparative effects of caffeine, beta-alanine, and their combination on mechanical, physiological, and perceptual responses to upper-body superset resistance training.

Martos-Arregui A, Li Z, Miras-Moreno S, Marcos-Frutos D, Jimenez-Martinez P, Alix-Fages C Eur J Appl Physiol. 2024; 125(3):837-850.

PMID: 39438314 DOI: 10.1007/s00421-024-05639-4.


Seeing the Truth About Double Blinding.

Redelmeier D, Zipursky J J Gen Intern Med. 2024; 39(16):3322-3329.

PMID: 39012541 PMC: 11618566. DOI: 10.1007/s11606-024-08887-4.


Optimizing perinatal wellbeing in pregnancy with obesity: a clinical trial with a multi-component nutrition intervention for prevention of gestational diabetes and infant growth and neurodevelopment impairment.

Perichart-Perera O, Reyes-Munoz E, Borboa-Olivares H, Rodriguez-Cano A, Solis Paredes J, Hernandez-Hernandez L Front Med (Lausanne). 2024; 11:1339428.

PMID: 38681052 PMC: 11045894. DOI: 10.3389/fmed.2024.1339428.


Double-anonymous peer review comes to JB.

OToole G J Bacteriol. 2023; 205(10):e0008022.

PMID: 37747191 PMC: 10601697. DOI: 10.1128/jb.00080-22.


Placebo effects in osteoarthritis: implications for treatment and drug development.

Neogi T, Colloca L Nat Rev Rheumatol. 2023; 19(10):613-626.

PMID: 37697077 PMC: 10615856. DOI: 10.1038/s41584-023-01021-4.


References
1.
Park J, Lee H, White A, Ernst E . Suggesting an alternative to the term "double-blind". Anesthesiology. 2002; 96(4):1034; author reply 1035. DOI: 10.1097/00000542-200204000-00044. View

2.
Forder P, Gebski V, Keech A . Allocation concealment and blinding: when ignorance is bliss. Med J Aust. 2005; 182(2):87-9. DOI: 10.5694/j.1326-5377.2005.tb06584.x. View

3.
Karanicolas P, Farrokhyar F, Bhandari M . Practical tips for surgical research: blinding: who, what, when, why, how?. Can J Surg. 2010; 53(5):345-8. PMC: 2947122. View

4.
Miller L, Stewart M . The blind leading the blind: use and misuse of blinding in randomized controlled trials. Contemp Clin Trials. 2010; 32(2):240-3. DOI: 10.1016/j.cct.2010.11.004. View

5.
Viergever R, Ghersi D . Information on blinding in registered records of clinical trials. Trials. 2012; 13:210. PMC: 3522538. DOI: 10.1186/1745-6215-13-210. View